carbostyril has been researched along with Stroke in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Gluud, C; Hróbjartsson, A; Jakobsen, JC; Korang, SK; Safi, S; Sethi, NJ; Skoog, M | 1 |
| Barone, FC; Hu, E; Lepore, J; Li, J; Poon, C; Qin, P; Rivera, K; Rosenbaum, DM; Willette, RN; Zhou, J; Zhuang, J | 1 |
| Leung, JG; Nelson, S | 1 |
| Rosenberg, PA; Zhang, Y | 1 |
| Avorn, J; Brookhart, MA; Choudhry, NK; Mogun, H; Patrick, A; Schneeweiss, S; Setoguchi, S; Wang, PS | 1 |
| Boissard, CG; Fan, W; Gribkoff, VK; Hewawasam, P; Knipe, J; Moon, SL; Starrett, JE | 1 |
1 review(s) available for carbostyril and Stroke
| Article | Year |
|---|---|
Antibiotics for secondary prevention of coronary heart disease.
Topics: Anti-Bacterial Agents; Cardiovascular Diseases; Cause of Death; Coronary Disease; Death, Sudden, Cardiac; Humans; Macrolides; Middle Aged; Myocardial Infarction; Quinolones; Randomized Controlled Trials as Topic; Secondary Prevention; Stroke | 2021 |
7 other study(ies) available for carbostyril and Stroke
| Article | Year |
|---|---|
The prolyl 4-hydroxylase inhibitor GSK360A decreases post-stroke brain injury and sensory, motor, and cognitive behavioral deficits.
Topics: Administration, Oral; Animals; Behavior, Animal; Brain; Brain Injuries; Cognition Disorders; Erythropoietin; Glycine; Hypoxia-Inducible Factor 1, alpha Subunit; Infarction, Middle Cerebral Artery; Male; Motor Activity; Organ Specificity; Prolyl Hydroxylases; Prolyl-Hydroxylase Inhibitors; Quinolones; Rats, Sprague-Dawley; RNA, Messenger; Sensation; Stroke; Vascular Endothelial Growth Factor A | 2017 |
Game Changers.
Topics: Acute Disease; Aminophenols; Aminopyridines; Benzodioxoles; Brain Ischemia; Cystic Fibrosis; Drug Combinations; Endovascular Procedures; Humans; Quinolones; Rectal Neoplasms; Stroke; Transanal Endoscopic Microsurgery | 2015 |
Torsades de pointes after administration of low-dose aripiprazole.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Diabetes Complications; Drug Monitoring; Heart Arrest; Humans; Hypertension; Male; Piperazines; Quinolones; Risk Factors; Schizophrenia; Stroke; Torsades de Pointes; Treatment Outcome | 2013 |
The essential nutrient pyrroloquinoline quinone may act as a neuroprotectant by suppressing peroxynitrite formation.
Topics: Animals; Brain; Cell Survival; Dose-Response Relationship, Drug; Fetus; Molsidomine; Neurons; Neuroprotective Agents; Nitric Oxide; Nitric Oxide Donors; Oxidative Stress; Peroxynitrous Acid; PQQ Cofactor; Quinolones; Quinones; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Stroke; Superoxides | 2002 |
Fatal stroke with aripiprazole.
Topics: Antipsychotic Agents; Dementia; Humans; Ischemic Attack, Transient; Piperazines; Quinolones; Stroke | 2005 |
Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications.
Topics: Administration, Oral; Aged; Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Benzodiazepines; Clozapine; Databases, Factual; Dementia; Dibenzothiazepines; Drug Utilization Review; Health Services for the Aged; Humans; Olanzapine; Pharmaceutical Services; Piperazines; Quetiapine Fumarate; Quinolones; Risk Assessment; Risperidone; Stroke; Thiazoles; Treatment Outcome | 2007 |
The synthesis and structure-activity relationships of 4-aryl-3-aminoquinolin-2-ones: a new class of calcium-dependent, large conductance, potassium (maxi-K) channel openers targeted for post-stroke neuroprotection.
Topics: Animals; Brain; Clone Cells; Disease Models, Animal; Electrophysiology; Large-Conductance Calcium-Activated Potassium Channels; Male; Membrane Potentials; Neuroprotective Agents; Oocytes; Patch-Clamp Techniques; Potassium Channels, Calcium-Activated; Quinolones; Rats; Stroke; Structure-Activity Relationship; Xenopus laevis | 2002 |